📊 QTTB Key Takeaways
Is Q32 Bio Inc. (QTTB) a Good Investment?
Q32 Bio exhibits severe contradictions between accounting profitability and operational cash flow. Despite reporting a 55.5% net margin and exceptional ROE/ROA, the company is burning $33.5M in operating cash annually. The extreme revenue and earnings growth (4993.6% and 99900% YoY) combined with non-operating gains suggests reliance on one-time licensing/partnership deals rather than sustainable core operations. At current burn rates, the company has approximately 1-2 years of cash runway before requiring capital raises or additional milestone events.
Why Buy Q32 Bio Inc. Stock? QTTB Key Strengths
- Strong balance sheet with $48.3M cash and zero debt
- Exceptional liquidity ratios (4.85x current and quick ratios)
- Reported high profitability metrics (71% ROE, 48.3% ROA) indicating asset efficiency
- Recent significant business developments evidenced by revenue spike
QTTB Stock Risks: Q32 Bio Inc. Investment Risks
- Severe operating cash flow burn of -$33.5M despite positive net income suggests non-cash gains and unsustainable operations
- Accounting profitability appears driven by non-recurring items (licensing/milestones) rather than core business
- Limited cash runway (approximately 1-2 years at current burn rate) requires continuous external funding or revenue generation
- Pharmaceutical sector inherent R&D risks with dependency on drug development pipeline success
- Cash burn rate (-62.4% FCF margin) indicates the reported profitability is illusory and operationally non-viable
Key Metrics to Watch
- Operating cash flow trend - critical to determine if burn rate improves or worsens
- Source and sustainability of revenue - clarify if from recurring operations or one-time partnerships/licensing
- Cash runway depletion rate - monitor quarterly burn to project runway remaining
- Pipeline advancement and clinical trial results - fundamental value drivers for biotech
- Future capital raise announcements - likely necessary given cash burn dynamics
Q32 Bio Inc. (QTTB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.85x current ratio provides a solid financial cushion.
QTTB Profit Margin, ROE & Profitability Analysis
QTTB vs Healthcare Sector: How Q32 Bio Inc. Compares
How Q32 Bio Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Q32 Bio Inc. Stock Overvalued? QTTB Valuation Analysis 2026
Based on fundamental analysis, Q32 Bio Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Q32 Bio Inc. Balance Sheet: QTTB Debt, Cash & Liquidity
QTTB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Q32 Bio Inc.'s revenue has declined by 40% over the 5-year period, indicating business contraction. The most recent EPS of $-6.58 indicates the company is currently unprofitable.
QTTB Revenue Growth, EPS Growth & YoY Performance
QTTB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | $1.0M | $-1.46 |
| Q2 2024 | N/A | $1.0M | $-1.42 |
| Q1 2024 | N/A | $1.0M | $-6.33 |
| Q3 2023 | N/A | -$28.8M | $0.51 |
| Q2 2023 | $354.0K | -$28.8M | $-0.51 |
| Q1 2023 | $802.0K | -$28.8M | $-0.50 |
| Q3 2022 | $802.0K | -$1.1M | $0.51 |
| Q2 2022 | $802.0K | -$1.1M | $-0.51 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Q32 Bio Inc. Dividends, Buybacks & Capital Allocation
QTTB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Q32 Bio Inc. (CIK: 0001661998)
📋 Recent SEC Filings
❓ Frequently Asked Questions about QTTB
What is the AI rating for QTTB?
Q32 Bio Inc. (QTTB) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are QTTB's key strengths?
Claude: Strong balance sheet with $48.3M cash and zero debt. Exceptional liquidity ratios (4.85x current and quick ratios).
What are the risks of investing in QTTB?
Claude: Severe operating cash flow burn of -$33.5M despite positive net income suggests non-cash gains and unsustainable operations. Accounting profitability appears driven by non-recurring items (licensing/milestones) rather than core business.
What is QTTB's revenue and growth?
Q32 Bio Inc. reported revenue of $53.7M.
Does QTTB pay dividends?
Q32 Bio Inc. does not currently pay dividends.
Where can I find QTTB SEC filings?
Official SEC filings for Q32 Bio Inc. (CIK: 0001661998) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is QTTB's EPS?
Q32 Bio Inc. has a diluted EPS of $2.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is QTTB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Q32 Bio Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is QTTB stock overvalued or undervalued?
Valuation metrics for QTTB: ROE of 71.0% (sector avg: 15%), net margin of 55.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy QTTB stock in 2026?
Our dual AI analysis gives Q32 Bio Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is QTTB's free cash flow?
Q32 Bio Inc.'s operating cash flow is $-33.5M, with capital expenditures of $0.0. FCF margin is -62.4%.
How does QTTB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 55.5% (avg: 12%), ROE 71.0% (avg: 15%), current ratio 4.85 (avg: 2).
Why is QTTB's return on equity (ROE) so high?
Q32 Bio Inc. has a return on equity of 71.0%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 55.5% net margin.